Toronto - Delayed Quote • CAD
Cardiol Therapeutics Inc. (CRDL.TO)
At close: April 26 at 3:59 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David G. Elsley MBA | President, CEO & Director | 748.1k | -- | -- |
| Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 294.8k | -- | -- |
| Mr. Bernard Lim B.Sc. | Chief Operating Officer | 515.9k | -- | -- |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 746.56k | -- | 1962 |
| Trevor Burns | Investor Relations | -- | -- | -- |
Cardiol Therapeutics Inc.
2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Corporate Governance
Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
May 17, 2024 - May 21, 2024
Cardiol Therapeutics Inc. Earnings Call
Related Tickers
MDP.TO Medexus Pharmaceuticals Inc.
1.9200
+3.23%
2HQ.F Tilray Brands, Inc.
1.6950
+2.73%
CPH.TO Cipher Pharmaceuticals Inc.
8.50
0.00%
CURA.TO Curaleaf Holdings, Inc.
6.78
+4.47%
CL.CN Cresco Labs Inc.
2.8200
+6.02%
CRON.TO Cronos Group Inc.
3.5300
+2.62%
AYR-A.CN Ayr Wellness Inc.
3.2500
+3.83%
VPH.TO Valeo Pharma Inc.
0.1150
+21.05%
0ET.SG Esperion Therapeutics Inc
1.8105
-0.17%
BHC.TO Bausch Health Companies Inc.
11.92
+1.10%